Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1959 1
1960 1
1961 3
1963 1
1964 3
1965 25
1966 37
1967 46
1968 63
1969 61
1970 109
1971 104
1972 98
1973 88
1974 130
1975 120
1976 67
1977 103
1978 105
1979 128
1980 108
1981 106
1982 115
1983 114
1984 122
1985 120
1986 92
1987 95
1988 76
1989 88
1990 90
1991 81
1992 88
1993 86
1994 77
1995 82
1996 67
1997 85
1998 88
1999 94
2000 103
2001 76
2002 87
2003 93
2004 94
2005 120
2006 109
2007 122
2008 108
2009 107
2010 126
2011 141
2012 163
2013 169
2014 163
2015 182
2016 160
2017 133
2018 147
2019 42
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

5,371 results
Results by year
Filters applied: . Clear all
Page 1
Advances in immunotherapy in multiple myeloma.
Boussi L and Niesvizky R. Curr Opin Oncol 2017 - Review. PMID 28877078
PURPOSE OF REVIEW: Here, we explore the significant progress made in the treatment of multiple myeloma, focusing on immunotherapy and the promise it has offered to patients suffering from advanced disease. RECENT FINDINGS: Multiple myeloma, a B-cell malignancy, is characterized by unregulated plasma cell growth in the bone marrow as well as strong immunosuppression in the tumor microenvironment. mAbs targeting tumor antigens overcome this, increasing T-cell activation, multiple myeloma cell death, and depth of response. ...
PURPOSE OF REVIEW: Here, we explore the significant progress made in the treatment of multiple myeloma, focusing on immunother …
CD38 targeted treatment for multiple myeloma.
Jelínek T, et al. Vnitr Lek 2018. PMID 30590941
CD38 antigen is highly and uniformly expressed on plasma cells and thus represents an ideal target for the treatment of multiple myeloma (MM) with anti-CD38 monoclonal antibodies (mAbs). ...Key words: acute myeloid leukemia - CD38 - daratumumab - isatuximab - multiple myeloma....
CD38 antigen is highly and uniformly expressed on plasma cells and thus represents an ideal target for the treatment of multiple m
Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
Castella M, et al. Int J Mol Sci 2018 - Review. PMID 30445802 Free PMC article.
Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal proliferation of malignant plasma cells in bone marrow. ...
Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal proliferation of malignant plasma
Emerging immune targets for the treatment of multiple myeloma.
Sohail A, et al. Immunotherapy 2018. PMID 29421983 Free PMC article.
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. ...
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refracto …
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L, et al. Clin Cancer Res 2019. PMID 30692097
PURPOSE: Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb) is required to understand which patients with multiple myeloma (MM) benefit the most from a given mAb, alone or in combination therapy. ...
PURPOSE: Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb) is required to understand which patients with multi
Immunotherapy for the treatment of multiple myeloma.
Jung SH, et al. Crit Rev Oncol Hematol 2017 - Review. PMID 28259300
Immunotherapy has recently emerged as a promising treatment for multiple myeloma (MM). There are now several monoclonal antibodies that target specific surface antigens on myeloma cells or the checkpoints of immune and myeloma cells. ...Dendritic cell vaccination is a safe strategy that has shown some efficacy in a subset of myeloma patients and may become a crucial part of MM treatment when combined with immunomodulatory drugs or immune check-point blockade. ...
Immunotherapy has recently emerged as a promising treatment for multiple myeloma (MM). There are now several monoclonal antibo …
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma.
Rafei H, et al. Am J Clin Oncol 2019 - Review. PMID 30557165
Multiple myeloma (MM) is a B-cell malignancy characterized by the abnormal proliferation of clonal plasma cells in the bone marrow leading to end-organ manifestations. ...The development of immunotherapy as a treatment modality for many types of cancers has led investigators to explore its use in MM in order to elicit myeloma-targeted immune responses, especially given that immune dysregulation is an underlying feature in the pathogenesis and progression of MM. ...
Multiple myeloma (MM) is a B-cell malignancy characterized by the abnormal proliferation of clonal plasma cells in the bone ma
5,371 results
Jump to page
Feedback